NKG2A checkpoint receptor expression on tumor-infiltrating CD8+ T cells restrains efficacy of immunotherapy

被引：0
|
作者：
van Hall, Thorbald
van Montfoort, Nadine
Piersma, Sytse
Sluijter, Marjolein
Welters, Marij J.
Andre, Pascale
Wagtmann, Nicolai
van der Burg, Sjoerd H.
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-2999
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2999
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Tumor cell secretome induces the expression of the immune checkpoint NKG2A on CD8+ T cells
    Rodriguez-Garcia, Gabriel J.
    Schares, Henry A.
    Bachmann, Brian O.
    Kim, Young J.
    Korrer, Michael J.
    Rathmell, Jeffrey C.
    JOURNAL OF IMMUNOLOGY, 2023, 210 (01):
  • [2] The inhibitory checkpoint molecule NKG2A is upregulated on tumor-infiltrating NK cells and CD8 T-cells in human head and neck tumors
    Korrer, Michael J.
    Kim, Young
    CANCER IMMUNOLOGY RESEARCH, 2019, 7 (02)
  • [3] HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8+ T lymphocytes
    Gooden, Marloes
    Lampen, Margit
    Jordanova, Ekaterina S.
    Leffers, Ninke
    Trimbos, J. Baptist
    van der Burg, Sjoerd H.
    Nijman, Hans
    van Hall, Thorbald
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (26) : 10656 - 10661
  • [4] Enriched HLA-E and CD94/NKG2A Interaction Limits Antitumor CD8+ Tumor-Infiltrating T Lymphocyte Responses
    Abd Hamid, Megat
    Wang, Ruo-Zheng
    Yao, Xuan
    Fan, Peiwen
    Li, Xi
    Chang, Xue-Mei
    Feng, Yaning
    Jones, Stephanie
    Maldonado-Perez, David
    Waugh, Craig
    Verrill, Clare
    Simmons, Alison
    Cerundolo, Vincenzo
    McMichael, Andrew
    Conlon, Christopher
    Wang, Xiyan
    Peng, Yanchun
    Dong, Tao
    CANCER IMMUNOLOGY RESEARCH, 2019, 7 (08) : 1293 - 1306
  • [5] Checkpoint Blockade Immunotherapy Relies on T-bet but Not Eomes to Induce Effector Function in Tumor-Infiltrating CD8+ T Cells
    Berrien-Elliott, Melissa M.
    Yuan, Jinyun
    Swier, Lauryn E.
    Jackson, Stephanie R.
    Chen, Collin L.
    Donlin, Maureen J.
    Teague, Ryan M.
    CANCER IMMUNOLOGY RESEARCH, 2015, 3 (02) : 116 - 124
  • [6] Enriched HLA-E and CD94/NKG2a interaction limits anti-tumor CD8+ tumor-infiltrating T lymphocyte responses
    Abd Hamid, M. H. B.
    Wang, R.
    Yao, X.
    Fan, P.
    Li, X.
    Chang, X.
    Feng, Y.
    Jones, S.
    Maldonado-Perez, D.
    Waugh, C.
    Verrill, C.
    Simmons, A.
    Cerundolo, V.
    McMichael, A.
    Conlon, C.
    Wang, X.
    Peng, Y.
    Dong, T.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 1252 - 1253
  • [7] Impaired enolase 1 glycolytic activity restrains effector functions of tumor-infiltrating CD8+ T cells
    Gemta, Lelisa F.
    Siska, Peter J.
    Nelson, Marin E.
    Gao, Xia
    Liu, Xiaojing
    Locasale, Jason W.
    Yagita, Hideo
    Slingluff, Craig L., Jr.
    Hoehn, Kyle L.
    Rathmell, Jeffrey C.
    Bullock, Timothy N. J.
    SCIENCE IMMUNOLOGY, 2019, 4 (31)
  • [8] The inhibitory receptor CD94/NKG2A on CD8+ tumor-infiltrating lymphocytes in colorectal cancer: a promising new druggable immune checkpoint in the context of HLAE/β2m overexpression
    Eugene, Juliette
    Jouand, Nicolas
    Ducoin, Kathleen
    Dansette, Delphine
    Oger, Romain
    Deleine, Cecile
    Leveque, Edouard
    Meurette, Guillaume
    Podevin, Juliette
    Matysiak, Tamara
    Bennouna, Jaafar
    Bezieau, Stephane
    Volteau, Christelle
    Thomas, Wassila El Alami
    Chetritt, Jerome
    Kerdraon, Olivier
    Fourquier, Pierre
    Thibaudeau, Emilie
    Dumont, Frederic
    Mosnier, Jean-Francois
    Toquet, Claire
    Jarry, Anne
    Gervois, Nadine
    Bossard, Celine
    MODERN PATHOLOGY, 2020, 33 (03) : 468 - 482
  • [9] Not All Tumor-Infiltrating CD8+ T Cells Are Created Equal
    Held, Werner
    Speiser, Daniel E.
    CANCER CELL, 2021, 39 (02) : 145 - 147
  • [10] Tumor-infiltrating CD8+ T cells as a biomarker for chemotherapy efficacy in unresectable hepatocellular carcinoma
    Kuwano, Akifumi
    Yada, Masayoshi
    Miyazaki, Yoshiko
    Tanaka, Kosuke
    Kurosaka, Kazuki
    Ohishi, Yoshihiro
    Masumoto, Akihide
    Motomura, Kenta
    ONCOLOGY LETTERS, 2023, 25 (06)
12345